Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Receivables - Net (2021 - 2025)

Historic Receivables - Net for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $107.1 million.

  • Mirum Pharmaceuticals' Receivables - Net rose 5632.86% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 5632.86%. This contributed to the annual value of $78.3 million for FY2024, which is 1518.07% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Receivables - Net of $107.1 million as of Q3 2025, which was up 5632.86% from $106.8 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Receivables - Net ranged from a high of $107.1 million in Q3 2025 and a low of $400000.0 during Q3 2021
  • Moreover, its 5-year median value for Receivables - Net was $47.8 million (2023), whereas its average is $47.9 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Receivables - Net skyrocketed by 398425.0% in 2022, and later skyrocketed by 1518.07% in 2024.
  • Mirum Pharmaceuticals' Receivables - Net (Quarter) stood at $3.3 million in 2021, then skyrocketed by 634.44% to $24.0 million in 2022, then surged by 183.27% to $68.0 million in 2023, then rose by 15.18% to $78.3 million in 2024, then skyrocketed by 36.85% to $107.1 million in 2025.
  • Its Receivables - Net was $107.1 million in Q3 2025, compared to $106.8 million in Q2 2025 and $95.9 million in Q1 2025.